Table 1.
Galidesivir activity in cell culture.
| Cell Line | SARS-CoV-2 Strain | Assay | Compound Pre-Incubation Period | EC50 (μM) | EC90 (μM) | CC50 (μM) | SI |
|---|---|---|---|---|---|---|---|
| Caco-2 | WA1/2020 | VYR | 24 h | n.d. | 14.19 | 82.8 | 5.8 * |
| Vero-76 | WA1/2020 | VYR | 24 h | n.d. | 10.94 | >295.7 | >27 * |
| CPE | 50.3 | 5.8 * | |||||
| Calu-3 | WA1/2020 | Imaging | 2 h ‡ | 14.15 | n.d. | >50 | >3.5 † |
* SI90; † SI50; ‡ The recommended period for pre-incubation with galidesivir is 24 h. CC, cytopathic concentration; CPE, cytopathic effect; EC, effective concentration; n.d., not determined; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SI, selectivity index; VYR, viral yield reduction.